ReviewTargeted oncology2018

Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.

Diwakar Davar et al.PubMed ↗Publisher ↗

No numbers read from the abstract.